Stacy Lindborg - Sep 6, 2025 Form 4 Insider Report for Imunon, Inc. (IMNN)

Role
President and CEO, Director
Signature
/s/ Susan Eylward, Attorney-in-Fact for Stacy Lindborg
Stock symbol
IMNN
Transactions as of
Sep 6, 2025
Transactions value $
$0
Form type
4
Date filed
9/9/2025, 04:14 PM
Previous filing
Aug 6, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Lindborg Stacy President and CEO, Director C/O IMUNON, INC., 997 LENOX DRIVE, SUITE 100, LAWRENCEVILLE /s/ Susan Eylward, Attorney-in-Fact for Stacy Lindborg 2025-09-09 0001813667

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IMNN Common Stock Options Exercise $0 +1.67K +86.96% $0.00 3.58K Sep 6, 2025 Direct F1
holding IMNN Common Stock 234 Sep 6, 2025 By 401(k) Plan

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IMNN Restricted Stock Options Exercise $0 -1.67K -100% $0.00 0 Sep 6, 2025 Common Stock 1.67K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Acquisition of common stock resulting from vesting of 100% of the restricted stock granted to Ms. Lindborg on September 6, 2024.
F2 Each restricted stock share represents a contingent right to receive one share of Imunon, Inc.'s common stock.
F3 On September 6, 2024, Ms. Lindborg received restricted stock representing 1,667 shares (as adjusted for the reverse stock split) subject to a one-year vesting schedule, vesting 100% on the first anniversary of the grant date. As restricted stock shares vest, the vested shares are automatically converted to vested common stock on a one-for-one basis on the vesting date.

Remarks:

On July 25, 2025, the Issuer effected a reverse stock split of Issuer Common Stock at a ratio of 1-for-15 (the "Reverse Stock Split"). As a result of the Reverse Stock Split, the shares of Issuer Common Stock, and the exercise price and shares of Issuer Common Stock underlying outstanding equity awards, have been adjusted accordingly versus any amounts previously reported by the Reporting Person. On August 21, 2025, the Issuer paid a 15% stock dividend, 0.15 shares of common stock per share of the Issuer's issued and outstanding shares of common stock, to stockholders of record as of August 7, 2025. As a result of the stock dividend, the shares of Issuer Common Stock have been adjusted accordingly versus any amounts previously reported by the Reporting Person.